<DOC>
	<DOC>NCT02011594</DOC>
	<brief_summary>There have been reports suggesting that anti-epidermal growth factor antibody nimotuzumab is advantageous for advanced esophageal cancer patients in combination with chemotherapy or radiotherapy. However, whether maintenance therapy of nimotuzumab provides benefit to advanced esophageal cancer patients is not known.</brief_summary>
	<brief_title>Phase II Study of Maintenance Treatment of Nimotuzumab for Advanced Esophageal Carcinoma</brief_title>
	<detailed_description>We design this clinical trial to confirm the efficacy of maintenance treatment of nimotuzumab after initial treatment.</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Squamous Cell</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<criteria>Patient who was confirmed stage IV esophageal carcinoma by pathologic histology or cytology. The sample size estimate: 20 cases per arm. Males or females aged ≥18 years, &lt; 75 years. Eastern Cooperative Oncology Group (ECOG) performance status 02. Life expectancy ≥12 weeks. Males and females should be contraceptive during the period of the trial until 8 weeks after the last administration of the drug. Adequate bone marrow, renal, and liver function are required. Able to comply with the required protocol and followup procedures, and able to receive oral medications. Institutional review boardapproved informed consent will be obtained for every patient before initiation of any trialspecific procedure or treatment. Any unstable systemic disease (including active infection, uncontrolled hypertension, unstable angina, congestive heart failure, myocardial infarction within the previous year, serious cardiac arrhythmia requiring medication, hepatic, renal, or metabolic disease). Allergy to antiEGFR antibody. Female subjects should not be pregnant or breastfeeding. Adequate hematological function: Absolute neutrophil count (ANC) ≥1.5 x 109/L, and Platelet count ≥100 x 109/L. Adequate renal function: Serum creatinine ≤ 1.5 x ULN, or ≥ 50 ml/min. Adequate liver function: total bilirubin &lt; 1.5 x upper limit of normal (ULN) and alanine aminotransferase (ALT) and aspartate aminotransferase (AST) &lt; 2.5 x ULN in the absence of liver metastases, or &lt; 5 x ULN in case of liver metastases. Patient assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>